CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis
TSX:CRON - Toronto Stock Exchange - CA22717L1013 - Common Stock - Currency: CAD
We assign a fundamental rating of 5 out of 10 to CRON. CRON was compared to 34 industry peers in the Pharmaceuticals industry. CRON has a great financial health rating, but its profitability evaluates not so good. CRON is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CRON was profitable.
In the past year CRON had a positive cash flow from operations.
CRON had negative earnings in 4 of the past 5 years.
CRON had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of CRON (3.52%) is better than 91.18% of its industry peers.
With an excellent Return On Equity value of 3.86%, CRON belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.52% | ||
| ROE | 3.86% | ||
| ROIC | N/A |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 34.93%, CRON belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
CRON's Profit Margin has declined in the last couple of years.
CRON's Gross Margin of 21.42% is on the low side compared to the rest of the industry. CRON is outperformed by 73.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 34.93% | ||
| GM | 21.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRON has more shares outstanding
Compared to 5 years ago, CRON has more shares outstanding
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 5.60 indicates that CRON is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.60, CRON belongs to the top of the industry, outperforming 97.06% of the companies in the same industry.
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.6 |
ROIC/WACCN/A
WACC8.33%
2.3 Liquidity
A Current Ratio of 18.84 indicates that CRON has no problem at all paying its short term obligations.
CRON has a better Current ratio (18.84) than 100.00% of its industry peers.
A Quick Ratio of 18.17 indicates that CRON has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 18.17, CRON belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.84 | ||
| Quick Ratio | 18.17 |
3. Growth
3.1 Past
CRON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 190.91%, which is quite impressive.
CRON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -50.78% yearly.
The Revenue has grown by 33.82% in the past year. This is a very strong growth!
Measured over the past years, CRON shows a very strong growth in Revenue. The Revenue has been growing by 37.71% on average per year.
EPS 1Y (TTM)190.91%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%320%
Revenue 1Y (TTM)33.82%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%26.7%
3.2 Future
Based on estimates for the next years, CRON will show a very negative growth in Earnings Per Share. The EPS will decrease by -21.14% on average per year.
Based on estimates for the next years, CRON will show a small growth in Revenue. The Revenue will grow by 1.87% on average per year.
EPS Next Y-144.2%
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%
EPS Next 5Y-21.14%
Revenue Next Year18.44%
Revenue Next 2Y12.81%
Revenue Next 3Y7.09%
Revenue Next 5Y1.87%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 18.36, the valuation of CRON can be described as rather expensive.
CRON's Price/Earnings ratio is rather cheap when compared to the industry. CRON is cheaper than 85.29% of the companies in the same industry.
CRON's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.75.
The Forward Price/Earnings Ratio is negative for CRON. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.36 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRON indicates a somewhat cheap valuation: CRON is cheaper than 61.76% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 125.9 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CRON's earnings are expected to decrease with -39.52% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%
5. Dividend
5.1 Amount
No dividends for CRON!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CRON (5/1/2025, 7:00:00 PM)
2.57
-0.02 (-0.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners13.13%
Inst Owner ChangeN/A
Ins Owners5.48%
Ins Owner ChangeN/A
Market Cap990.50M
Analysts74.55
Price Target3.68 (43.19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1006.46%
Min EPS beat(2)296.08%
Max EPS beat(2)1716.84%
EPS beat(4)3
Avg EPS beat(4)340.81%
Min EPS beat(4)-684.31%
Max EPS beat(4)1716.84%
EPS beat(8)5
Avg EPS beat(8)171.4%
EPS beat(12)6
Avg EPS beat(12)82.3%
EPS beat(16)8
Avg EPS beat(16)61.24%
Revenue beat(2)1
Avg Revenue beat(2)-2.63%
Min Revenue beat(2)-14.99%
Max Revenue beat(2)9.73%
Revenue beat(4)3
Avg Revenue beat(4)0.24%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)9.73%
Revenue beat(8)4
Avg Revenue beat(8)-1.68%
Revenue beat(12)5
Avg Revenue beat(12)-4.39%
Revenue beat(16)7
Avg Revenue beat(16)-4.15%
PT rev (1m)0.47%
PT rev (3m)1.09%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)100%
EPS NY rev (1m)-44.43%
EPS NY rev (3m)3.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.17%
Revenue NY rev (1m)2.63%
Revenue NY rev (3m)0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.36 | ||
| Fwd PE | N/A | ||
| P/S | 6.09 | ||
| P/FCF | 125.9 | ||
| P/OCF | 38.01 | ||
| P/B | 0.67 | ||
| P/tB | 0.72 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.14
EY5.45%
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)0.02
FCFY0.79%
OCF(TTM)0.07
OCFY2.63%
SpS0.42
BVpS3.82
TBVpS3.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.52% | ||
| ROE | 3.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 34.93% | ||
| GM | 21.42% | ||
| FCFM | 4.84% |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 140.9% | ||
| Cap/Sales | 11.18% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 13.85% | ||
| Current Ratio | 18.84 | ||
| Quick Ratio | 18.17 | ||
| Altman-Z | 5.6 |
F-Score6
WACC8.33%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190.91%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%320%
EPS Next Y-144.2%
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)33.82%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%26.7%
Revenue Next Year18.44%
Revenue Next 2Y12.81%
Revenue Next 3Y7.09%
Revenue Next 5Y1.87%
EBIT growth 1Y26.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year90.36%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y112.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.99%
OCF growth 3YN/A
OCF growth 5YN/A